Although IFN-β is used in MS for its effects as an immunomodulator, mounting evidence suggests that the stabilization of the BBB is also crucial for IFN-β effectiveness in controlling MS symptoms (33, 34). The gene discussed is IFNB1; the disease is myeloid sarcoma.